Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BDA-366 是一种有效的 Bcl2 拮抗剂,以高亲和力和选择性 (Ki = 3.3 nM) 结合 Bcl2-BH4 结构域。 BDA-366 诱导 Bcl2 的构象变化,从而消除其抗凋亡功能,将其从存活分子转变为细胞死亡诱导剂。 BDA-366 抑制肺癌细胞的生长。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 547 | 现货 | ||
2 mg | ¥ 783 | 现货 | ||
5 mg | ¥ 1,330 | 现货 | ||
10 mg | ¥ 2,220 | 现货 | ||
25 mg | ¥ 3,970 | 现货 | ||
50 mg | ¥ 5,820 | 现货 | ||
100 mg | ¥ 7,920 | 现货 |
产品描述 | BDA-366, a potent Bcl2 antagonist, selectively binds the Bcl2-BH4 domain with high affinity (Ki = 3.3 nM), inducing a conformational change that nullifies its antiapoptotic function, thereby transforming it into a pro-apoptotic entity. This compound effectively suppresses lung cancer cell growth[1]. |
体外活性 | NSC 228155 promotes transactivation of several RTKs, including ErbB2 and ErbB3, Insulin R and IGF-1 R receptors in the cells. It stimulates dimerization of sEGFR domain II[1]. NSC 228155 can rapidly move across cell membranes and disperse within both cytoplasmic and nuclear compartments. It rapidly generates hydrogen peroxide within cells[2]. NSC 228155 is also a potent inhibitor of KIX-KID interaction(IC50 = 0.36 μM), but it is not particularly selective against CREB-mediated gene transcription in HEK 293T cells[3]. |
分子量 | 423.5 |
分子式 | C24H29N3O4 |
CAS No. | 1909226-00-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 5 mg/mL (11.8 mM)
DMSO: 78 mg/mL (184.2 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.3613 mL | 11.8064 mL | 23.6128 mL | 59.0319 mL |
5 mM | 0.4723 mL | 2.3613 mL | 4.7226 mL | 11.8064 mL | |
10 mM | 0.2361 mL | 1.1806 mL | 2.3613 mL | 5.9032 mL | |
DMSO | 20 mM | 0.1181 mL | 0.5903 mL | 1.1806 mL | 2.9516 mL |
50 mM | 0.0472 mL | 0.2361 mL | 0.4723 mL | 1.1806 mL | |
100 mM | 0.0236 mL | 0.1181 mL | 0.2361 mL | 0.5903 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BDA-366 1909226-00-1 Apoptosis BCL Inhibitor Antitumor Bcl-2 Family inhibit Bcl2-BH4 domain Anticancer BDA 366 Antiapoptotic function BDA366 Lung cancer inhibitor